Inari Medical FY2025 EPS Estimate Boosted by William Blair

Inari Medical, Inc. (NASDAQ:NARI - Free Report) - Research analysts at William Blair boosted their FY2025 EPS estimates for Inari Medical in a report released on Thursday, October 31st. William Blair analyst M. Kaczor now expects that the company will earn $0.18 per share for the year, up from their prior forecast of $0.13. William Blair has a "Outperform" rating on the stock. The consensus estimate for Inari Medical's current full-year earnings is ($0.74) per share.

NARI has been the topic of a number of other research reports. Leerink Partnrs upgraded Inari Medical to a "hold" rating in a research report on Tuesday, September 3rd. Needham & Company LLC reaffirmed a "hold" rating on shares of Inari Medical in a research report on Tuesday, October 29th. Wells Fargo & Company dropped their price target on shares of Inari Medical from $84.00 to $65.00 and set an "overweight" rating for the company in a research report on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft started coverage on Inari Medical in a research note on Friday, August 9th. They set a "buy" rating and a $68.00 price target on the stock. Finally, Robert W. Baird boosted their price objective on Inari Medical from $66.00 to $67.00 and gave the company an "outperform" rating in a report on Tuesday, October 29th. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Inari Medical has an average rating of "Hold" and an average target price of $58.89.

Inari Medical Trading Up 0.4 %

Inari Medical stock traded up $0.19 during midday trading on Monday, hitting $48.93. 794,714 shares of the stock were exchanged, compared to its average volume of 1,001,480. Inari Medical has a fifty-two week low of $36.73 and a fifty-two week high of $67.13. The stock has a market capitalization of $2.86 billion, a price-to-earnings ratio of -36.10 and a beta of 0.96. The stock's 50-day simple moving average is $43.66 and its 200 day simple moving average is $46.15.

Insider Buying and Selling at Inari Medical

In other Inari Medical news, CFO Mitch C. Hill sold 3,000 shares of the firm's stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $45.13, for a total value of $135,390.00. Following the sale, the chief financial officer now directly owns 179,600 shares in the company, valued at $8,105,348. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director William Hoffman sold 40,000 shares of the business's stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $50.05, for a total value of $2,002,000.00. Following the completion of the sale, the director now directly owns 561,233 shares of the company's stock, valued at $28,089,711.65. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Mitch C. Hill sold 3,000 shares of the company's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $45.13, for a total transaction of $135,390.00. Following the completion of the transaction, the chief financial officer now owns 179,600 shares of the company's stock, valued at $8,105,348. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 131,000 shares of company stock valued at $6,161,340. Insiders own 10.60% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. State of Alaska Department of Revenue boosted its stake in shares of Inari Medical by 462.4% during the first quarter. State of Alaska Department of Revenue now owns 31,095 shares of the company's stock worth $1,491,000 after buying an additional 25,566 shares during the period. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Inari Medical in the 1st quarter valued at $30,000. Texas Permanent School Fund Corp increased its stake in Inari Medical by 1.5% in the 1st quarter. Texas Permanent School Fund Corp now owns 44,858 shares of the company's stock valued at $2,152,000 after buying an additional 664 shares during the period. Swiss National Bank raised its position in Inari Medical by 0.6% during the 1st quarter. Swiss National Bank now owns 102,300 shares of the company's stock worth $4,908,000 after buying an additional 600 shares during the last quarter. Finally, ProShare Advisors LLC lifted its stake in shares of Inari Medical by 4.7% in the 1st quarter. ProShare Advisors LLC now owns 12,319 shares of the company's stock worth $591,000 after acquiring an additional 553 shares during the period. Hedge funds and other institutional investors own 90.98% of the company's stock.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.